Increased Plasma Levels of the Soluble Form of Fas Ligand in Patients With Acute Myocardial Infarction and Unstable Angina Pectoris
|
|
- Scott Casey
- 5 years ago
- Views:
Transcription
1 Journal of the American College of Cardiology Vol. 39, No. 4, by the American College of Cardiology ISSN /02/$22.00 Published by Elsevier Science Inc. PII S (01) Increased Plasma Levels of the Soluble Form of Fas Ligand in Patients With Acute Myocardial Infarction and Unstable Angina Pectoris Myocardial Infarction Masumi Shimizu, MD,* Keisuke Fukuo, MD,* Shigekazu Nagata, PHD, Toshimitsu Suhara, MD,* Masashi Okuro, MD,* Kenshi Fujii, MD, Yorihiko Higashino, MD, Masaki Mogi, MD,* Yasuko Hatanaka, MD,* Toshio Ogihara, MD* Suita and Osaka, Japan OBJECTIVES To examine whether the Fas/Fas ligand system is involved in the pathogenesis of acute myocardial infarction (AMI), we measured the levels of the soluble form of the Fas ligand (sfasl) in the plasma of patients with AMI and stable or unstable angina pectoris (AP). BACKGROUND The Fas ligand (FasL) is rapidly cleaved off by a metalloproteinase from the cell membrane to become a soluble form as a cytokine. Fas is expressed in most cells, including cardiomyocytes, whereas FasL is mainly expressed in inflammatory cells such as macrophages, which are greatly accumulated in unstable plaque. METHODS Thirty patients with AMI, 10 patients with unstable AP, 10 patients with stable AP and 30 control subjects were enrolled in the present study. RESULTS Plasma sfasl levels were significantly elevated on hospital admission in patients with AMI and unstable AP, compared with control subjects. Time-course studies revealed that plasma sfasl levels rapidly decreased within 3 h and then increased again after percutaneous transluminal coronary angioplasty in patients with AMI, but not in patients with stable AP. Importantly, the sfasl levels were higher in the coronary sinus than in the circulation. In addition, in vitro studies showed that the expression of FasL messenger ribonucleic acid was upregulated in mononuclear cells isolated from patients with AMI and that hypoxia stimulated the release of sfasl from isolated mononuclear cells. CONCLUSIONS This demonstration of elevated levels of sfasl in patients with AMI and unstable AP suggests that activation of the Fas/FasL system may play a pathogenic role in AMI and acute coronary syndromes. (J Am Coll Cardiol 2002;39:585 90) 2002 by the American College of Cardiology Apoptosis is an important physiologic cell death mechanism that serves to remove damaged or unwanted cells. However, the dysregulation of apoptosis has been implicated in many human diseases, such as cancer, neurodegenerative diseases and ischemic heart diseases (1). Recent studies in pathology have shown that many cardiomyocytes die by apoptosis as well as necrosis during myocardial infarction (2,3). Although the molecular mechanism of this process is not clear, cardiomyocyte apoptosis can be induced by many stimuli, including hypoxia (4), ischemia/reperfusion (5), mechanical stretch (6), tumor necrosis factor- (TNF- ) (7) and reactive oxygen species (8). Yaoita et al. (9) recently reported that pretreatment with the caspase inhibitor ZVAD-fmk resulted in a reduction in infarct size and an improvement of acute functional variables in a rat model of acute myocardial infarction (AMI). In addition, Daemen et al. (10) reported that at the time of reperfusion, administration of the anti-apoptotic agents insulin-like growth factor-1 and From the *Department of Geriatric Medicine, and Department of Genetics, Osaka University Medical School, Suita, Japan; and Sakurabashi-Watanabe Hospital, Sakurabashi, Osaka, Japan. This work was supported by a grant from the Osaka Medical Research Foundation for Incurable Diseases. Manuscript received September 29, 2000; revised manuscript received November 7, 2001, accepted November 29, ZVAD-fmk prevented not only renal apoptosis but also inflammation, suggesting that the inhibition of apoptosis may be a useful therapeutic strategy for treatment in these ischemic animal models. However, it is not clear whether inhibition of apoptosis is beneficial in human AMI. To address this issue, it is necessary to define the key molecules that regulate cardiomyocyte apoptosis during AMI. The Fas ligand (FasL; also called the CD95 or APO-1 ligand) is a cytokine that mediates apoptosis by binding to its receptor, Fas (also called CD95 or APO-1) through activating caspases (11). Fas is expressed almost ubiquitously in a variety of cells, including cardiomyocytes, whereas FasL is mainly expressed in natural killer cells, activated T cells and macrophages (12) as well as immuneprivileged tissues of the eye and testes (13). The findings that cardiomyocytes die by apoptosis in association with upregulation of Fas under hypoxia (14) and that FasL is constitutively expressed in the myocardium (15) suggest that Fas-mediated cardiomyocyte apoptosis may be involved in the mechanism of AMI. On the other hand, Nelson et al. (16) recently reported that the FasL transgenic heart shows no myocardial apoptosis or necrosis but has proinflammatory consequences, resulting in cardiac hypertrophy and
2 586 Shimizu et al. JACC Vol. 39, No. 4, 2002 Plasma Soluble Fas Ligand Levels in AMI February 20, 2002: Abbreviations and Acronyms AMI acute myocardial infarction AP angina pectoris CHF congestive heart failure CK-MB creatine kinase-mb isoenzyme ELISA enzyme-linked immunosorbent assay mfasl membrane-bound Fas ligand sfasl soluble Fas ligand PBMCs peripheral blood mononuclear cells PCR polymerase chain reaction PTCA percutaneous transluminal coronary angioplasty TNF- tumor necrosis factor- fibrosis, suggesting that FasL could mediate proinflammatory signals in cardiovascular diseases. Importantly, FasL, a member of the TNF family, is rapidly cleaved off by a metalloproteinase from the membrane to become a soluble form (sfasl) as well as TNF- (17). In human studies, sfasl has been detected in the serum of patients with myocarditis (18) and congestive heart failure (CHF) (19), in the cerebrospinal fluid after a severe head injury (20) and in the bronchoalveolar lavage fluid of patients with acute respiratory distress syndrome (21). In contrast, Nishigaki et al. (22) reported that plasma levels of soluble Fas, but not sfasl, were elevated in patients with CHF. To examine the possible participation of the Fas/ FasL system in the pathogenesis of AMI, we measured the levels of plasma sfasl in patients with AMI without CHF. We found that plasma sfasl levels were significantly increased in the early phases of AMI and that the levels of sfasl were correlated with its severity. METHODS Subjects. We included 30 patients with AMI, 10 patients with unstable angina pectoris (AP) and 10 patients with stable AP. The average time from the onset of symptoms to hospital admission was h (range 1 to 12). All patients with unstable AP had experienced ischemic chest pain at rest within the preceding 48 h (i.e., Braunwald s class IIIB [23]), but they had no evidence of myocardial necrosis by enzymatic criteria. Transient ST-T segment depression or T-wave inversion, or both, were present in all patients. Study protocol. CORONARY ANGIOGRAPHY. In all of the 30 patients with AMI, coronary angiography was performed immediately after admission. One patient was treated with percutaneous transluminal coronary recanalization through intracoronary infusion of urokinase, and 29 patients were treated with direct percutaneous transluminal coronary angioplasty (PTCA). We excluded AMI patients with CHF, concomitant inflammatory diseases, cancer or other significant heart diseases. All patients gave written, informed consent to be included in the study, which was approved by the Ethics Committee on Human Research of Osaka University. BLOOD SAMPLING AND ASSAY FOR sfasl. Blood sampling for measuring sfasl concentrations was taken from the peripheral vein on admission before PTCA or thrombolysis in all patients with AMI, and in five patients it was repeated at 3, 6, 12, 18 and 24 h after admission. In five patients with AMI, blood samples were drawn from the coronary sinus, using a 7F Swan-Ganz catheter, as well as from the peripheral vein, at the same time in the same patient. The samples were then centrifuged immediately at 3,000 rpm (4 C, 15 min) and stored at 80 C until assay. We measured the plasma levels of sfasl by an enzyme-linked immunosorbent assay (ELISA), as described previously (17). MEASUREMENT OF HEMODYNAMIC VARIABLES. A Swan- Ganz catheter was inserted into the femoral vein immediately after admission, before coronary angiography, and was kept in place during the first two days in all patients. The pulmonary artery wedge pressure and cardiac output in all patients with AMI were measured by using a 7F Swan- Ganz thermodilution catheter (Baxter Healthcare Corp., Santa Ana, California), and the cardiac index was calculated as the cardiac output/body surface area ratio. Then left ventricular end-diastolic pressure was measured by using a 5F pigtail catheter, and left ventriculography was performed. The left ventricular ejection fraction was calculated using a centerline method. MEASUREMENT OF FasL mrna LEVELS. Peripheral blood mononuclear cells (PBMCs) were obtained from heparinized blood by Ficoll-Paque Plus (Pharmacia LKB Biotechnology, Piscataway, New Jersey) gradient centrifugation. Total ribonucleic acid (RNA) was prepared using Isogen (Nippon Gene, Tokyo, Japan). One microgram of total RNA was reverse transcribed in a final volume of 10 l with 200 U of Super Script II (Life Technologies, Tokyo, Japan) containing 0.5 mmol/l of deoxynucleotide triphosphate, 10 mmol/l of dithiothreitol and 100 ng of the antisense primer (5 -GCCGAAAAACGTCTGAGATT) for human FasL. After incubation at 42 C for 60 min, 1 l of the reaction mixture was used for polymerase chain reaction (PCR), which was carried out with 2.5 U of Taq deoxyribonucleic acid (DNA) polymerase (Pharmacia) in 50 l of reaction buffer containing 0.25 mmol/l of dntp, 600 ng of each sense primer (5 -TGTTTCAGCTCTTCCACCTA) and antisense primer (5 -GTTCCTCATGTAGACCTTGT). The conditions for PCR were as follows: 94 C for 1 min; 55 C for 2 min; and 72 C for 3 min, for 25 cycles with a thermal cycler (Perkin Elmer, Norwalk, Connecticut). To amplify human G3PDH mrna, 100 ng of random hexamers (Gibco, Tokyo, Japan) was used in complementary DNA synthesis, and 30 cycles of PCR (at 94 C for 1 min, 55 C for 2 min and 72 C for 3 min) were performed using a commercial primer set (Clontech, Palo Alto, California). The amplified products were subjected to electrophoresis on 1.2% agarose gels and visualized by ethidium bromide staining. The predicted size of the FasL fragment was 344 base pairs, and that of G3PDH was 983 base pairs.
3 JACC Vol. 39, No. 4, 2002 February 20, 2002: Shimizu et al. Plasma Soluble Fas Ligand Levels in AMI 587 Table 1. Patient Characteristics Control Subjects (n 30) Patients With Stable AP (n 10) Patients With Unstable AP (n 10) Patients With AMI (n 30) Age (yrs) Men/women 21/9 6/4 7/3 23/7 Hypertension Smoking Diabetes mellitus Hyperlipidemia Data are presented as the mean value SD or number of patients or control subjects. AMI acute myocardial infarction; AP angina pectoris. HYPOXIA EXPERIMENTS. Isolated PBMCs cultured in serum-free Roswell Park Memorial Institute 1640 medium were exposed for the indicated times to the ambient oxygen concentration of 1% oxygen, 5% carbon dioxide, 94% nitrogen at 37 C (using a controlled incubator with carbon dioxide/oxygen monitoring and carbon dioxide/nitrogen gas sources). The sfasl levels in the supernatant were measured by ELISA, as described earlier. Statistical analysis. All data are expressed as the mean value SD. A combination of analysis of variance, based on ranks, and a multiple comparisons procedure (i.e., the Bonferroni/Dunn procedure) was used. A p value 0.05 was considered significant. RESULTS Patient characteristics. Table 1 shows the clinical characteristics of the patients with stable AP, the patients with unstable AP, the patients with AMI and the control subjects. There were no significant differences in age or gender ratio among these four groups. There were significantly more hypertensive patients, smokers and diabetics in the three groups of patients with ischemic heart disease than in the control group. Plasma sfasl levels on hospital admission. The plasma sfasl levels were elevated in patients with AMI and unstable AP on admission ( h after symptom onset), compared with the control subjects (Fig. 1). However, the sfasl levels were not elevated in patients with stable AP. Correlation of plasma sfasl levels with clinical variables. Next, we examined the correlation of plasma sfasl levels with the maximal levels of creatine kinase MB isoenzyme (CK-MB), a marker of infarct size, and the hemodynamic variables within the first two days after admission. There was no significant correlation between the plasma sfasl levels on admission and the maximal levels of CK-MB or hemodynamic variables, such as the cardiac index (Fig. 2, A and B). Time course changes of plasma sfasl in patients with AMI. To examine the physiologic significance of the measurement of plasma sfasl levels, we examined the time course of the changes of plasma sfasl levels in five patients with AMI after admission. As shown in Figure 3A, the Figure 1. Plasma levels of sfasl on hospital admission in patients with stable and unstable angina pectoris (AP) and patients with acute myocardial infarction (AMI). Blood sampling for measuring the concentrations of soluble Fas ligand (sfasl) were taken from the peripheral vein on admission in all patients. plasma sfasl levels decreased rapidly within 3 h after admission. However, they increased again after PTCA and then returned to the basal level within 24 h. In contrast, the sfasl levels remained high at least within 24 h after admission in two patients with severe clinical complications such as re-occlusion and ventricular fibrillation (data not shown). Importantly, there was no increase in the levels of sfasl after PTCA in patients with stable AP. Levels of sfasl in the coronary sinus. We measured the sfasl levels in blood samples obtained from the coronary sinus in five patients with AMI whose culprit lesions located at left anterior descending coronary artery, and we compared them with those obtained from the peripheral vein at the same time in the same patient. As shown in Figure 3B, the level of sfasl was significantly higher in the coronary sinus than in the peripheral vein, indicating that local concentrations of sfasl may be much higher in the culprit lesion. Expression of FasL and release of sfasl in PBMCs. Recent pathologic studies have shown that unstable plaque from patients with acute coronary syndromes contains many more monocytes and macrophages, FasL-expressing cells, compared with stable plaque (24). To address the source of sfasl released in the circulation, we measured the levels of FasL mrna in PBMCs isolated from three patients with AMI and the control subjects. As shown in Figure 4A, FasL mrna expression in isolated PBMCs was significantly upregulated in a patient with AMI, compared with control subjects. However, this upregulation disappeared at 10 days after admission. Similar results were obtained in two other patients with AMI. In addition, in vitro cell culture studies showed that hypoxia (1% oxygen) significantly stimulated the release of sfasl from PBMCs isolated from patients with AMI (Fig. 4B). These findings indicate that one of the sources of sfasl could be circulating mononuclear cells.
4 588 Shimizu et al. JACC Vol. 39, No. 4, 2002 Plasma Soluble Fas Ligand Levels in AMI February 20, 2002: Figure 2. Correlation of plasma soluble Fas ligand (sfasl) levels with the maximal levels of creatine kinase-mb isoenzyme (CK-MB) (A) and with the cardiac index (B). DISCUSSION In the present study, we demonstrated for the first time that sfasl levels in the circulation were elevated at the early phase in patients with AMI and unstable AP, compared with control subjects. Soluble FasL may serve as a local cytokine that induces cardiomyocyte apoptosis during AMI. The Fas ligand, a member of the growing TNF family, is synthesized as a type II membrane protein that induces apoptosis in Fasexpressing cells. The membrane-bound FasL (mfasl) can be cleaved by a metalloproteinase to become sfasl (17,25). Although both mfasl and secreted sfasl appear to be biologically active, the physiologic functions of sfasl have not been elucidated. Tanaka et al. (25) reported that sfasl inhibits Fas-mediated lymphocyte apoptosis. However, Brown and Savill (26) recently reported that phagocytosis triggers macrophage release of sfasl and induces apoptosis of bystander monocytes. Matute-Bello et al. (21) also reported that the bronchoalveolar lavage concentration of sfasl at the onset of acute respiratory distress syndrome was significantly higher in patients who died and that bronchoalveolar lavage from patients with acute respiratory distress syndrome induced apoptosis of distal lung epithelial cells. These observations suggest that high concentrations of sfasl may induce apoptosis in Fas-bearing cells in a paracrine pathway if these cells are sensitized to Fasmediated apoptosis (27,28). Because hypoxia has been shown to upregulate Fas expression in cardiomyocytes and microglial cells (14,29), cardiomyocytes may be sensitized to Fas-mediated apoptosis during AMI. In addition, we have shown that sfasl levels in the coronary sinus were much higher than those in the circulation. Taken together, these findings suggest that high local concentrations of sfasl in the culprit lesion could facilitate cardiomyocyte apoptosis during AMI. However, there was no significant correlation between the plasma sfasl levels on admission and the maximal levels of CK-MB or hemodynamic variables, such as the cardiac index, in patients with AMI. Although the mechanism by which plasma sfasl levels are elevated in patients with AMI and unstable AP is not clear at present, Figure 3. Time course of the changes in plasma soluble Fas ligand (sfasl) levels and the differences in sfasl levels between the coronary sinus and peripheral vein. For the time-course experiment, peripheral blood sampling was repeated at 3, 6, 12, 18 and 24 h after admission in five patients with acute myocardial infarction (AMI) (A). Blood samples were collected from the coronary sinus and the peripheral vein at the same time in the same patient with AMI (B). AP angina pectoris; PTCA percutaneous transluminal coronary angioplasty.
5 JACC Vol. 39, No. 4, 2002 February 20, 2002: Shimizu et al. Plasma Soluble Fas Ligand Levels in AMI 589 Figure 4. The Fas ligand (FasL) mrna expression and soluble Fas ligand (sfasl) release in mononuclear cells isolated from patients with acute myocardial infarction (AMI). Basal levels of FasL mrna of mononuclear cells isolated from patients with AMI and from the control subjects (A). The mrna from 1A12 cells (FasL-overexpressing cells) was used as a positive control. Time course changes in sfasl levels after hypoxia in the supernatant from mononuclear cells isolated from patients with AMI (B). it should be noted that the levels of plasma sfasl changed rapidly after the onset of AMI (Fig. 3). Thus, it is possible that in some patients plasma sfasl concentrations may have already returned to the basal levels on admission, because the time from the onset of symptoms to admission ranged from 1 to 12 h. In addition, the levels of plasma sfasl could rapidly increase again in response to many forms of stress, including reperfusion (Fig. 3). Furthermore, the finding that sfasl levels were significantly higher in the coronary sinus than in the peripheral vein suggests that sfasl may serve mainly as a local cytokine in culprit lesions. Taken together, we assume that measuring the maximal levels of sfasl in the circulation, or the levels of sfasl in the coronary sinus, would be more appropriate ways of determining the correlation between the levels of sfasl and these clinical variables. Soluble FasL may serve as a proinflammatory factor. It has been shown that FasL can induce biologic functions unrelated to cell death, such as the induction of proinflammatory effects (30,31). For example, Ottonello et al. (32) recently reported that sfasl, at concentrations incapable of inducing cell apoptosis, has potent chemotactic properties toward human neutrophilic polymorphonuclear leukocytes. Seino et al. (33) also reported that the chemotactic activity of sfasl against phagocytes is independent of the death domain-mediated apoptosis. In addition, Nelson et al. (16) reported that FasL expression in the heart is proinflammatory, but in contrast to other examples of FasL-mediated inflammation, the consequences appear to be mild, resulting in hypertrophy and interstitial changes rather than tissue destruction. Thus, it could be possible that sfasl may also serve as a proinflammatory factor in patients with AMI and unstable AP. Mechanism for the elevation of plasma sfasl. The mechanism of an increase in the plasma levels of sfasl in patients with AMI and unstable AP is not clear at the present time. However, we demonstrated that FasL mrna expression of the circulating mononuclear cells was upregulated in the early phase of AMI, and it was downregulated in the late phase, when plasma sfasl returned to the control levels. Thus, one of the sources of sfasl could be circulating mononuclear cells. Recent histologic studies have shown that inflammatory cells such as monocytes and macrophages are greatly accumulated in unstable plaque obtained from patients with AMI and unstable AP, compared with stable plaque (24). In the present study, the levels of sfasl in the coronary sinus were higher than those in the circulation. In addition, plasma sfasl levels increased again after PTCA in the patients with AMI, but not in the patients with stable AP. Furthermore, hypoxia stimulated the release of sfasl from mononuclear cells isolated from patients with AMI. Taken together, these observations suggest that mononuclear cells accumulated in unstable plaque may serve as a source of sfasl in patients with AMI. On the other hand, Wollert et al. (15) recently reported that FasL, as well as Fas, are constitutively expressed in the rat myocardium. Thus, hypoxia/reperfusion could stimulate the release of sfasl from the myocardium, as well as inflammatory cells. It has been proposed that expression of FasL by some tissues contributes to their immune privilege status by preventing the infiltration of inflammatory cells (13). Thus, if FasL expression is downregulated by the conversion of mfasl to sfasl during hypoxia/reperfusion, it could promote the infiltration of inflammatory cells into the myocardium in patients with AMI and unstable AP. However, further studies are needed to clarify these points. Conclusions. We have demonstrated that plasma sfasl levels are elevated in patients with AMI and unstable AP and that hypoxia stimulated the release of sfasl from mononuclear cells isolated from patients with AMI. These findings may provide further insights into the mechanism underlying the pathogenesis of AMI and acute coronary syndromes.
6 590 Shimizu et al. JACC Vol. 39, No. 4, 2002 Plasma Soluble Fas Ligand Levels in AMI February 20, 2002: Acknowledgments We thank Taeko Kaimoto for her technical assistance and Tomoko Hironaka for her secretarial assistance. Reprint requests and correspondence: Dr. Keisuke Fukuo, Department of Geriatric Medicine, Osaka University Medical School, 2-2 Yamadaoka, Suita, Osaka , Japan. REFERENCES 1. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995;267: Misao J, Hayakawa Y, Ohno M, Kato S, Fujiwara T, Fujiwara H. Expression of bcl-2 protein, an inhibitor of apoptosis, and Bax, an accelerator of apoptosis, in ventricular myocytes of humans with myocardial infarction. Circulation 1996;94: Saraste A, Pulkki K, Kallajoki M, Henriksen K, Parvinen M, Voipio- Pulkki LM. Apoptosis in human acute myocardial infarction. Circulation 1997;95: Long X, Boluyt MO, Hipolito ML, et al. p53 and the hypoxiainduced apoptosis of cultured neonatal rat cardiac myocytes. J Clin Invest 1997;99: Webster KA, Discher DJ, Kaiser S, Hernandez O, Sato B, Bishopric NH. Hypoxia-activated apoptosis of cardiac myocytes requires reoxygenation or a ph shift and is independent of p53. J Clin Invest 1999;104: Cheng W, Li B, Kajstura J, et al. Stretch-induced programmed myocyte cell death. J Clin Invest 1995;96: Krown KA, Page MT, Nguyen C, et al. Tumor necrosis factor-alpha induced apoptosis in cardiac myocytes: involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest 1996;98: Adderley SR, Fitzgerald DJ. Oxidative damage of cardiomyocytes is limited by extracellular regulated kinases 1/2-mediated induction of cyclooxygenase-2. J Biol Chem 1999;274: Yaoita H, Ogawa K, Maehara K, Maruyama Y. Attenuation of ischemia/reperfusion injury in rats by a caspase inhibitor. Circulation 1998;97: Daemen MA, van t Veer C, Denecker G, et al. Inhibition of apoptosis induced by ischemia-reperfusion prevents inflammation. J Clin Invest 1999;104: Nagata S. Apoptosis by death factor. Cell 1997;88: Iwai K, Miyawaki T, Takizawa T, et al. Differential expression of bcl-2 and susceptibility to anti-fas mediated cell death in peripheral blood lymphocytes, monocytes, and neutrophils. Blood 1994;84: Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995;270: Tanaka M, Ito H, Adachi S, et al. Hypoxia induces apoptosis with enhanced expression of Fas antigen messenger RNA in cultured neonatal rat cardiomyocytes. Circ Res 1994;75: Wollert KC, Heineke J, Westermann J, et al. The cardiac Fas (APO-1/CD95) receptor/fas ligand system: relation to diastolic wall stress in volume-overload hypertrophy in vivo and activation of the transcription factor AP-1 in cardiac myocytes. Circulation 2000;101: Nelson DP, Setser E, Hall DG, et al. Proinflammatory consequences of transgenic Fas ligand expression in the heart. J Clin Invest 2000;105: Tanaka M, Suda T, Haze K, et al. Fas ligand in human serum. Nat Med 1996;2: Toyozaki T, Hiroe M, Tanaka M, Nagata S, Ohwada H, Marumo F. Levels of soluble Fas ligand in myocarditis. Am J Cardiol 1998;82: Yamaguchi S, Yamaoka M, Okuyama M, et al. Elevated circulating levels and cardiac secretion of soluble Fas ligand in patients with congestive heart failure. Am J Cardiol 1999;83: Ertel W, Keel M, Stocker R, et al. Detectable concentrations of Fas ligand in cerebrospinal fluid after severe head injury. J Neuroimmunol 1997;80: Matute-Bello G, Liles WC, Steinberg KP, et al. Soluble Fas ligand induces epithelial cell apoptosis in humans with acute lung injury (ARDS). J Immunol 1999;163: Nishigaki K, Minatoguchi S, Seishima M, et al. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure. J Am Coll Cardiol 1997;29: Braunwald E. Unstable angina: a classification. Circulation 1993;80: Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes: implications for plaque rupture. Circulation 1994;90: Tanaka M, Itai T, Adachi M, Nagata S. Downregulation of Fas ligand by shedding. Nat Med 1998;4: Brown SB, Savill J. Phagocytosis triggers macrophage release of Fas ligand and induces apoptosis of bystander leukocytes. J Immunol 1999;162: Tanaka M, Suda T, Yatomi T, Nakamura N, Nagata S. Lethal effect of recombinant human Fas ligand in mice pretreated with Propionibacterium acnes. J Immunol 1997;158: Suhara T, Fukuo K, Sugimoto T, et al. Hydrogen peroxide induces up-regulation of Fas in human endothelial cells. J Immunol 1998;160: Vogt M, Bauer MK, Ferrari D, Schulze Osthoff K. Oxidative stress and hypoxia/reoxygenation trigger CD95 (APO-1/Fas) ligand expression in microglial cells. FEBS Lett 1998;429: Miwa K, Asano M, Horai R, Iwakura Y, Nagata S, Suda T. Caspase-1 independent IL-1 release and inflammation induced by the apoptosis inducer Fas ligand. Nat Med 1998;4: Chen J-J, Sun Y, Nabel GJ. Regulation of the proinflammatory effects of Fas ligand (CD95L). Science 1998;282: Ottonello L, Tortolina G, Amelotti M, Dallegri F. Soluble Fas ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes. J Immunol 1999;162: Seino K, Iwabuchi K, Kayagaki N, et al. Chemotactic activity of soluble Fas ligand against phagocytes. J Immunol 1998;161:
12 Lead EKG Chapter 4 Worksheet
Match the following using the word bank. 1. A form of arteriosclerosis in which the thickening and hardening of the vessels walls are caused by an accumulation of fatty deposits in the innermost lining
More informationCardiovascular Disorders Lecture 3 Coronar Artery Diseases
Cardiovascular Disorders Lecture 3 Coronar Artery Diseases By Prof. El Sayed Abdel Fattah Eid Lecturer of Internal Medicine Delta University Coronary Heart Diseases It is the leading cause of death in
More informationBIOCHEMICAL INVESTIGATIONS IN THE DIAGNOSTICS OF CARDIOVASCULAR DISORDERS. As. MARUSHCHAK M.I.
BIOCHEMICAL INVESTIGATIONS IN THE DIAGNOSTICS OF CARDIOVASCULAR DISORDERS As. MARUSHCHAK M.I. Heart attack symptoms Acute MI Measurement of cardiac enzyme levels Measure cardiac enzyme levels at regular
More informationJournal of the American College of Cardiology Vol. 35, No. 5, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 35, No. 5, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)00546-5 CLINICAL
More informationS everal studies of apoptosis in the heart have been
362 ORIGINAL ARTICLE Tempero spatial dissociation between the expression of Fas and apoptosis after coronary occlusion Q Z Feng, T D Li, L X Wei, X Qiao, J Yi, L Wang, T S Yang... See end of article for
More informationMyocardial Infarction
Myocardial Infarction MI = heart attack Defined as necrosis of heart muscle resulting from ischemia. A very significant cause of death worldwide. of these deaths, 33% -50% die before they can reach the
More informationRelationship between transcardiac gradient of endothelin-1 and left ventricular remodelling in patients with first anterior myocardial infarction
European Heart Journal (2003) 24, 346 355 Relationship between transcardiac gradient of endothelin-1 and left ventricular remodelling in patients with first anterior myocardial infarction T. Tsutamoto
More informationE. Cervio, P. Danieli, C. Ciuffreda, F. Pisano, M. Roccio, M. Gnecchi. The authors have no financial disclosures to declare
16 th ISCT Annual Meeting SOLUBLE FACTORS RELEASED BY HUMAN MESENCHYMAL STEM CELLS OF FETAL ORIGIN LEAD TO CARDIOMYOCYTE PROTECTION THROUGH THE INHIBITION OF PRO-APOPTOTIC SIGNALING E. Cervio, P. Danieli,
More informationJournal Club Semmler Lorenz
Beer et al. 2015 - Analysis of the Secretome of Apoptotic Peripheral Blood Mononuclear Cells: Impact of Released Proteins and Exosomes for Tissue Regeneration Journal Club 13.11.2017 1 Introduction to
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL Clinical perspective It was recently discovered that small RNAs, called micrornas, circulate freely and stably in human plasma. This finding has sparked interest in the potential
More informationAcute coronary syndrome. Dr LM Murray Chemical Pathology Block SA
Acute coronary syndrome Dr LM Murray Chemical Pathology Block SA13-2014 Acute myocardial infarction (MI) MI is still the leading cause of death in many countries It is characterized by severe chest pain,
More informationIschemic heart disease
Ischemic heart disease Introduction In > 90% of cases: the cause is: reduced coronary blood flow secondary to: obstructive atherosclerotic vascular disease so most of the time it is called: coronary artery
More informationNon-Invasive Evaluation of Coronary Vasospasm Using a Combined Hyperventilation and Cold-Pressure-Test Perfusion CMR Protocol
Journal of Cardiovascular Magnetic Resonance (2007) 9, 759 764 Copyright c 2007 Informa Healthcare USA, Inc. ISSN: 1097-6647 print / 1532-429X online DOI: 10.1080/10976640701544662 Non-Invasive Evaluation
More informationBiomarkers in cardiovascular disease. Felix J. Rogers, DO, FACOI April 29, 2018
Biomarkers in cardiovascular disease Felix J. Rogers, DO, FACOI April 29, 2018 Biomarkers NIH: A biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal biological
More information1) Severe, crushing substernal chest pain 2) radiate to the neck, jaw, epigastrium, or left arm. 3- rapid and weak pulse 4- nausea (posterior MI).
1) Severe, crushing substernal chest pain 2) radiate to the neck, jaw, epigastrium, or left arm. 3- rapid and weak pulse 4- nausea (posterior MI). 5- cardiogenic shock (massive MIs >40% of the left ventricle)
More informationIschemic Heart Disease
Ischemic Heart Disease Dr Rodney Itaki Lecturer Division of Pathology University of Papua New Guinea School of Medicine & Health Sciences Division of Pathology General Consideration Results from partial
More informationReperfusion Injury: How Can We Reduce It?
MI/CAD: Practical Question in Management of AMI Patients Reperfusion Injury: How Can We Reduce It? Hyun-Jai Cho, M.D., Ph.D Cardiovascular Center & Department of Internal Medicine Seoul National University
More informationJournal of the American College of Cardiology Vol. 38, No. 4, by the American College of Cardiology ISSN /01/$20.
Journal of the American College of Cardiology Vol. 38, No. 4, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01477-2 Diabetes
More informationUncovering the mechanisms of wound healing and fibrosis
Any Questions??? Ask now or contact support support@sabiosciences.com 1-888-503-3187 International customers: SABio@Qiagen.com Uncovering the mechanisms of wound healing and fibrosis Webinar related questions:
More informationDyslipidemia Endothelial dysfunction Free radicals Immunologic
ATHEROSCLEROSIS Hossein Mehrani Professor of Clinical Biochemistry Definition Atherosclerosis: Is a chronic inflammatory process characterized by plaque formation within the vessel wall of arteries and
More informationAcute coronary syndromes
Acute coronary syndromes 1 Acute coronary syndromes Acute coronary syndromes results primarily from diminished myocardial blood flow secondary to an occlusive or partially occlusive coronary artery thrombus.
More informationConcurrent Subarachnoid Hemorrhage and Acute Myocardial Infarction: A Case Report
Concurrent subarachnoid hemorrhage and AMI 155 Concurrent Subarachnoid Hemorrhage and Acute Myocardial Infarction: A Case Report Chen-Chuan Cheng 1, Wen-Shiann Wu 1, Chun-Yen Chiang 1, Tsuei-Yuang Huang
More informationrenoprotection therapy goals 208, 209
Subject Index Aldosterone, plasminogen activator inhibitor-1 induction 163, 164, 168 Aminopeptidases angiotensin II processing 64 66, 214 diabetic expression 214, 215 Angiotensin I intrarenal compartmentalization
More informationProceedings of the 36th World Small Animal Veterinary Congress WSAVA
www.ivis.org Proceedings of the 36th World Small Animal Veterinary Congress WSAVA Oct. 14-17, 2011 Jeju, Korea Next Congress: Reprinted in IVIS with the permission of WSAVA http://www.ivis.org 14(Fri)
More informationBiomarkers in Acute Cardiac Disease Samir Arnaout, M.D.FESC Associate Professor of Medicine Internal Medicine i & Cardiology American University of Beirut Time course of the appearance of various markers
More informationIschemic Postconditioning During Primary Percutaneous Coronary Intervention Mechanisms and Clinical Application Jian Liu, MD FACC FESC FSCAI Chief Phy
Ischemic Postconditioning During Primary Percutaneous Coronary Intervention Mechanisms and Clinical Application Jian Liu, MD FACC FESC FSCAI Chief Physician, Professor of Medicine Department of Cardiology,
More informationPathophysiology of Cardiovascular System. Dr. Hemn Hassan Othman, PhD
Pathophysiology of Cardiovascular System Dr. Hemn Hassan Othman, PhD hemn.othman@univsul.edu.iq What is the circulatory system? The circulatory system carries blood and dissolved substances to and from
More informationSevere Coronary Vasospasm Complicated with Ventricular Tachycardia
Severe Coronary Vasospasm Complicated with Ventricular Tachycardia Göksel Acar, Serdar Fidan, Servet İzci and Anıl Avcı Kartal Koşuyolu High Specialty Education and Research Hospital, Cardiology Department,
More informationObesity is related to a higher inflammatory responsive state of circulating cells after stimulation of toll like receptor 2 and 4.
Toll Like Receptor Response and traditional risk factors for atherosclerosis: Obesity is related to a higher inflammatory responsive state of circulating cells after stimulation of toll like receptor 2
More informationIntracoronary Serum Smooth Muscle Myosin Heavy Chain Levels Following PTCA may Predict Restenosis
Clinical Studies Intracoronary Serum Smooth Muscle Myosin Heavy Chain Levels Following PTCA may Predict Restenosis Yasuhiro TSUCHIO,MD,ShigetoNAITO, MD, Akihiko NOGAMI,MD, Hiroshi HOSHIZAKI, MD, ShigeruOSHIMA,
More informationEducation/Training: (Begin with entry into college and include postdoctoral training)
BIOGRAPHICAL SKETCH (PI) Name: Hideshi Okada Degree(s): M.D., Ph.D. Position/Title: Postdoctoral Fellow Education/Training: (Begin with entry into college and include postdoctoral training) Institution
More informationAcute Coronary Syndrome
ACUTE CORONOARY SYNDROME, ANGINA & ACUTE MYOCARDIAL INFARCTION Administrative Consultant Service 3/17 Acute Coronary Syndrome Acute Coronary Syndrome has evolved as a useful operational term to refer to
More informationJournal of the American College of Cardiology Vol. 37, No. 2, by the American College of Cardiology ISSN /01/$20.
Journal of the American College of Cardiology Vol. 37, No. 2, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)01133-5 Coronary
More informationDiabetes and the Heart
Diabetes and the Heart Association of Specialty Professors April 4, 2013 Jorge Plutzky, MD Co-Director, Preventive Cardiology Director, The Lipid Clinic Cardiovascular Division Brigham and Women s Hospital
More informationDr. Hany M. Abo-Haded
BY Dr. Hany M. Abo-Haded Pediatric Cardiology Unit, Mansoura Universty Children Hospital, Mansoura, Egypt Co-authors: Dina S El-Agamy and Mohamed A Elkablawy Background Doxorubicin (DOX) is an anthracycline
More informationshehab Moh Tarek ... ManarHajeer
3 shehab Moh Tarek... ManarHajeer In the previous lecture we discussed the accumulation of oxygen- derived free radicals as a mechanism of cell injury, we covered their production and their pathologic
More informationOUTCOME OF THROMBOLYTIC AND NON- THROMBOLYTIC THERAPY IN ACUTE MYOCARDIAL INFARCTION
OUTCOME OF THROMBOLYTIC AND NON- THROMBOLYTIC THERAPY IN ACUTE MYOCARDIAL INFARCTION FEROZ MEMON*, LIAQUAT CHEEMA**, NAND LAL RATHI***, RAJ KUMAR***, NAZIR AHMED MEMON**** OBJECTIVE: To compare morbidity,
More informationSystemic inflammation after myocardial infarction
Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2013 Systemic inflammation after myocardial infarction Rudiger, Alain DOI:
More informationTHE COMPLEX RELATION BETWEEN VULNERABILITY AND ISCHEMIA a paradigm shift
THE COMPLEX RELATION BETWEEN VULNERABILITY AND ISCHEMIA a paradigm shift Angioplasty Summit TCT ASIA Seoul, Korea, april 23rd, 2008 Nico H. J. Pijls, MD, PhD Catharina Hospital, Eindhoven, The Netherlands
More informationStable Ischemic Heart Disease. Ivan Anderson, MD RIHVH Cardiology
Stable Ischemic Heart Disease Ivan Anderson, MD RIHVH Cardiology Outline Review of the vascular biology of atherosclerosis Why not just cath everyone with angina? Medical management of ischemic cardiomyopathy
More informationLnformation Coverage Guidance
Lnformation Coverage Guidance Coverage Indications, Limitations, and/or Medical Necessity Abstract: B-type natriuretic peptide (BNP) is a cardiac neurohormone produced mainly in the left ventricle. It
More informationAfter occlusion of a coronary artery, deprivation of oxygen
Involvement of CD95/Apo1/Fas in Cell Death After Myocardial Ischemia I. Jeremias, MD; C. Kupatt, MD; A. Martin-Villalba, MD; H. Habazettl, MD; J. Schenkel, PhD; P. Boekstegers, MD; K.M. Debatin, MD Background
More information2017 Cardiology Survival Guide
2017 Cardiology Survival Guide Chapter 4: Cardiac Catheterization/Percutaneous Coronary Intervention A cardiac catheterization involves a physician inserting a thin plastic tube (catheter) into an artery
More informationAcute Myocardial Infarction
Acute Myocardial Infarction Hafeza Shaikh, DO, FACC, RPVI Lourdes Cardiology Services Asst.Program Director, Cardiology Fellowship Associate Professor, ROWAN-SOM Acute Myocardial Infarction Definition:
More informationDiagnosis and Management of Acute Myocardial Infarction
Diagnosis and Management of Acute Myocardial Infarction Acute Myocardial Infarction (AMI) occurs as a result of prolonged myocardial ischemia Atherosclerosis leads to endothelial rupture or erosion that
More informationIn Vivo Animal Models of Heart Disease. Why Animal Models of Disease? Timothy A Hacker, PhD Department of Medicine University of Wisconsin-Madison
In Vivo Animal Models of Heart Disease Timothy A Hacker, PhD Department of Medicine University of Wisconsin-Madison Why Animal Models of Disease? Heart Failure (HF) Leading cause of morbidity and mortality
More informationACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS. Choompone Sakonwasun, MD (Hons), FRCPT
ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS Choompone Sakonwasun, MD (Hons), FRCPT Types of Adaptive Immunity Types of T Cell-mediated Immune Reactions CTLs = cytotoxic T lymphocytes
More informationAcute Coronary Syndrome. Sonny Achtchi, DO
Acute Coronary Syndrome Sonny Achtchi, DO Objectives Understand evidence based and practice based treatments for stabilization and initial management of ACS Become familiar with ACS risk stratification
More informationContrast Induced Nephropathy
Contrast Induced Nephropathy O CIAKI refers to an abrupt deterioration in renal function associated with the administration of iodinated contrast media O CIAKI is characterized by an acute (within 48 hours)
More informationThe MAIN-COMPARE Study
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
More informationAPOPTOSIS, NECROSIS AND CANCER. Dr. S. P. Pattanayak
APOPTOSIS, NECROSIS AND CANCER Dr. S. P. Pattanayak LEARNING OBJECTIVES At the end of the lecture, students should be able to: Know the importance of cell death. Define various modes of cell death. Identify
More informationAcute Myocardial Infarction. Willis E. Godin D.O., FACC
Acute Myocardial Infarction Willis E. Godin D.O., FACC Acute Myocardial Infarction Definition: Decreased delivery of oxygen and nutrients to the myocardium Myocardial tissue necrosis causing irreparable
More informationΒΙΟΔΕΙΚΤΕΣ ΣΤΗΝ ΚΑΡΔΙΑΚΗ ΑΝΕΠΑΡΚΕΙΑ. ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ Καθηγητής Καρδιολογίας
ΕΘΝΙΚΟ ΚΑΙ ΚΑΠΟΔΙΣΤΡΙΑΚΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΑΘΗΝΩΝ ΙΑΤΡΙΚΗ ΣΧΟΛΗ Ά ΚΑΡΔΙΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ Διευθυντής: Καθηγητής Δημήτριος Τούσουλης ΒΙΟΔΕΙΚΤΕΣ ΣΤΗΝ ΚΑΡΔΙΑΚΗ ΑΝΕΠΑΡΚΕΙΑ ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ Καθηγητής Καρδιολογίας
More informationCase Report Thirty Years Later: Evolution of Treatment for Acute Left Main Coronary Artery Occlusion
Case Reports in Cardiology Volume 2016, Article ID 7360682, 4 pages http://dx.doi.org/10.1155/2016/7360682 Case Report Thirty Years Later: Evolution of Treatment for Acute Left Main Coronary Artery Occlusion
More informationCoronary Artery Embolism From Ruptured Plaque in the Left Main Trunks With Difficulty in Detection of Culprit Lesion: A Case Report
J Cardiol 2005 Mar; 453: 115 121 1 Coronary Artery Embolism From Ruptured Plaque in the Left Main Trunks With Difficulty in Detection of Culprit Lesion: A Case Report Takatomi Eiji Shinya Yasuhiro Kazuo
More informationRole of CMR in heart failure and cardiomyopathy
Role of CMR in heart failure and cardiomyopathy Hajime Sakuma Department of Radiology, Mie University Late gadolinium enhancement (LGE) LGE MRI can demonstrate site of necrosis, fibrosis or deposition
More informationObjectives. Acute Coronary Syndromes; The Nuts and Bolts. Overview. Quick quiz.. How dose the plaque start?
Objectives Acute Coronary Syndromes; The Nuts and Bolts Michael P. Gulseth, Pharm. D., BCPS Pharmacotherapy II Spring 2006 Compare and contrast pathophysiology of unstable angina (UA), non-st segment elevation
More informationDiabetic Patients: Current Evidence of Revascularization
Diabetic Patients: Current Evidence of Revascularization Alexandra J. Lansky, MD Yale University School of Medicine University College of London The Problem with Diabetic Patients Endothelial dysfunction
More informationIntroduction: 年 Fas signal-mediated apoptosis. PI3K/Akt
Fas-ligand (CD95-L; Fas-L) Fas (CD95) Fas (apoptosis) 年 了 不 度 Fas Fas-L 力 不 Fas/Fas-L T IL-10Fas/Fas-L 不 年 Fas signal-mediated apoptosis 度降 不 不 力 U-118, HeLa, A549, Huh-7 MCF-7, HepG2. PI3K/Akt FasPI3K/Akt
More informationProlonged Oral Morphine Therapy for Severe Angina Pectoris
Vol. 19 No. 5 May 2000 Journal of Pain and Symptom Management 393 Clinical Note Prolonged Oral Morphine Therapy for Severe Angina Pectoris Meir Mouallem, MD, Eli Schwartz, MD, and Zvi Farfel, MD Department
More informationROMANIAN ACADEMY INSTITUTE OF CELLULAR BIOLOGY AND PATHOLOGY NICOLAE SIMIONESCU. PhD THESIS Summary
ROMANIAN ACADEMY INSTITUTE OF CELLULAR BIOLOGY AND PATHOLOGY NICOLAE SIMIONESCU PhD THESIS Summary INVOLVEMENT OF ALARMIN HMGB1 IN INFLAMMATORY PROCESSES ASSOCIATED WITH VASCULAR DYSFUNCTION IN HYPERLIPIDEMIA
More informationEffect of Short-term Maximal Exercise on BNP Plasma Levels in. Healthy Individuals
1 Effect of Short-term Maximal Exercise on BNP Plasma Levels in Healthy Individuals Jan Krupicka, MD, Tomas Janota, MD, Zdislava Kasalova, MD, Jaromir Hradec, MD 3rd Department of Internal Medicine, 1st
More informationVentricular Arrhythmias in Acute MI Patients Undergoing Primary PCI
Ventricular Arrhythmias in Acute MI Patients Undergoing Primary PCI Bulent Gorenek MD FACC FESC Eskişehir Osmangazi University Cardiology Department Eskisehir-Turkey I do not have any potential conflict
More informationMeasuring Natriuretic Peptides in Acute Coronary Syndromes
Measuring Natriuretic Peptides in Acute Coronary Syndromes Peter A. McCullough, MD, MPH, FACC, FACP, FAHA, FCCP Consultant Cardiologist Chief Academic and Scientific Officer St. John Providence Health
More informationSilencing of the Activated Protein-1 Transcription Factor JunD Exacerbates Ischemia/Reperfusion-induced Cerebral Injury
Silencing of the Activated Protein-1 Transcription Factor JunD Exacerbates Ischemia/Reperfusion-induced Cerebral Injury Martin F. Reiner, Candela Diaz-Cañestro, Alexander Akhmedov, Heidi Amstalden, Sylvie
More informationHEART AND SOUL STUDY OUTCOME EVENT - MORBIDITY REVIEW FORM
REVIEW DATE REVIEWER'S ID HEART AND SOUL STUDY OUTCOME EVENT - MORBIDITY REVIEW FORM : DISCHARGE DATE: RECORDS FROM: Hospitalization ER Please check all that may apply: Myocardial Infarction Pages 2, 3,
More informationTYPE II MI. KC ACDIS LOCAL CHAPTER March 8, 2016
TYPE II MI KC ACDIS LOCAL CHAPTER March 8, 2016 TYPE 2 MI DEFINITION: Acute coronary syndrome (ACS) encompasses a continuum of myocardial ischemia and infarction, which can make the diagnostic and coding
More informationReperfusion Effects After Cardiac Ischemia
Reperfusion Effects After Cardiac Ischemia Dave Milzman, MD, FACEP Professor and Assistant Dean for Clinical Research Georgetown University School of Medicine Research Director, Depts of Trauma and Emerg
More informationThe system Fas/Fas-L in SLE
The system Fas/Fas-L in SLE NATALIA BELUSHKINA 1, ABDELMAROUF MOHIELDEIN 2, ULIANA PETROVA 3. 1,2 Department of Biochemistry, 3 Deparment of immunology 1 Sechenov Moscow Medical Academy, Research Institute
More informationUPDATE ON THE MANAGEMENTACUTE CORONARY SYNDROME. DR JULES KABAHIZI, Psc (Rwa) Lt Col CHIEF CONSULTANT RMH/KFH 28 JUNE18
UPDATE ON THE MANAGEMENTACUTE CORONARY SYNDROME DR JULES KABAHIZI, Psc (Rwa) Lt Col CHIEF CONSULTANT RMH/KFH 28 JUNE18 INTRODUCTION The clinical entities that comprise acute coronary syndromes (ACS)-ST-segment
More informationWHI Form Report of Cardiovascular Outcome Ver (For items 1-11, each question specifies mark one or mark all that apply.
WHI Form - Report of Cardiovascular Outcome Ver. 6. COMMENTS To be completed by Physician Adjudicator Date Completed: - - (M/D/Y) Adjudicator Code: OMB# 095-044 Exp: 4/06 -Affix label here- Clinical Center/ID:
More informationA Long-Term and Slow-Releasing Hydrogen Sulfide Donor Protects against Myocardial. Ischemia/Reperfusion Injury
Supporting Information A Long-Term and Slow-Releasing Hydrogen Sulfide Donor Protects against Myocardial Ischemia/Reperfusion Injury Xiaotian Sun 1 *, Wenshuo Wang 2, Jing Dai 3, Sheng Jin 4, Jiechun Huang
More informationPrehospital and Hospital Care of Acute Coronary Syndrome
Ischemic Heart Diseases Prehospital and Hospital Care of Acute Coronary Syndrome JMAJ 46(8): 339 346, 2003 Katsuo KANMATSUSE* and Ikuyoshi WATANABE** * Professor, Second Internal Medicine, Nihon University,
More informationHeart failure congestive heart failure, or CHF
Heart failure Heart failure (also called congestive heart failure, or CHF) is a frequent end point of many of the conditions In the United States alone, CHF affects nearly 5 million individuals annually,
More informationMyocarditis in Infants and Children
in Infants and Children Guideline of the German Society of Pediatric Cardiology Thomas Paul, Carsten Tschöpe, Reinhard Kandolf Children s Heart Center, Georg-August-University, Göttingen Department of
More informationASSOCIATION OF SYSTEMIC INFLAMMATION WITH ARTERIAL STIFFNESS IN HYPERTENSION
ASSOCIATION OF SYSTEMIC INFLAMMATION WITH ARTERIAL STIFFNESS IN HYPERTENSION Jung-Sun Kim a and Sungha Park a,b, a Division of Cardiology, b Cardiovascular Genome Center, Yonsei Cardiovascular Center,
More informationComplete Proximal Occlusion of All Three Main Coronary Arteries Complicated With a Left Main Coronary Aneurysm: A Case Report
J Cardiol 2004 Nov; 44 5 : 201 205 Complete Proximal Occlusion of All Three Main Coronary Arteries Complicated With a Left Main Coronary Aneurysm: A Case Report Takatoshi Hiroshi Akira Takahiro Masayasu
More informationAcetylcholine coronary spasm provocation testing: Revaluation in the real clinical practice
Research article Interventional Cardiology Acetylcholine coronary spasm provocation testing: Revaluation in the real clinical practice Background: Japanese Circulation Society guidelines for coronary spastic
More information12/18/2009 Resting and Maxi Resting and Max mal Coronary Blood Flow 2
Coronary Artery Pathophysiology ACS / AMI LeRoy E. Rabbani, MD Director, Cardiac Inpatient Services Director, Cardiac Intensive Care Unit Professor of Clinical Medicine Major Determinants of Myocardial
More informationTo estimate the serum level of N-terminal pro-brain natriuretic peptide levels in acute coronary syndrome
Original Research Article To estimate the serum level of N-terminal pro-brain natriuretic peptide levels in acute coronary syndrome Mohamed Yasar Arafath 1, K. Babu Raj 2* 1 First Year Post Graduate, 2
More informationCase Report. Faculty of Medicine, Oita University 2 Department of Cardiology, Hakuaikai Hospital
Case Report Manifestation of ST-Segment Elevation in Right Precordial Leads during schemia at a Right Ventricular Outflow Tract rea in a Patient with rugada Syndrome Naohiko Takahashi MD 1, Tetsuji Shinohara
More informationA case of post myocardial infarction ventricular septal rupture CHRISTOFOROS KOBOROZOS, MD
A case of post myocardial infarction ventricular septal rupture CHRISTOFOROS KOBOROZOS, MD NAVAL HOSPITAL OF ATHENS case presentation Female, 81yo Hx: diabetes mellitus, hypertension, chronic anaemia presented
More informationReeju Manandhar, Chaofeng Sun. Original article
Original article Association of different blood parameters with the early patency of Infarct related artery in ST elevation Myocardial Infarction, a comparative analysis. Reeju Manandhar, Chaofeng Sun
More informationCommon Codes for ICD-10
Common Codes for ICD-10 Specialty: Cardiology *Always utilize more specific codes first. ABNORMALITIES OF HEART RHYTHM ICD-9-CM Codes: 427.81, 427.89, 785.0, 785.1, 785.3 R00.0 Tachycardia, unspecified
More informationThe MAIN-COMPARE Registry
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
More informationCytokines, adhesion molecules and apoptosis markers. A comprehensive product line for human and veterinary ELISAs
Cytokines, adhesion molecules and apoptosis markers A comprehensive product line for human and veterinary ELISAs IBL International s cytokine product line... is extremely comprehensive. The assays are
More informationConflict of Interest Slide
Comparison of six- month clinical outcomes, event free survival rates of patients undergoing enhanced external counterpulsation (EECP) for coronary artery disease in the United States and Europe Ozlem
More informationPhiladelphia College of Osteopathic Medicine Annual Progress Report: 2011 Formula Grant
Philadelphia College of Osteopathic Medicine Annual Progress Report: 2011 Formula Grant Reporting Period January 1, 2012 June 30, 2012 Formula Grant Overview The Philadelphia College of Osteopathic Medicine
More informationTransmural, haemorrhagic myocardial infarction. Clinical, angiographic, and necropsy findings. after intracoronary streptokinase
BrHeartj 1982; 48: 546-51 Transmural, haemorrhagic myocardial infarction after intracoronary streptokinase Clinical, angiographic, and necropsy findings DETLEF G MATHEY, JOACHIM SCHOFER, KARL-HEINZ KUCK,
More informationCoronary Spasm as a Cause of Coronary Thrombosis and Myocardial Infarction
Case Reports Coronary Spasm as a Cause of Coronary Thrombosis and Myocardial Infarction Masashi HORIMOTO, M.D., Takashi TAKENAKA, M.D., Keiichi IGARASHI, M.D. Masafumi FUJIWARA, M.D., and Sanjay BATRA,
More informationNstemi But Stemi-De Winters Sign
Cardiology and Angiology: An International Journal 3(3): 162-166, 2015, Article no.ca.2015.015 ISSN: 2347-520X SCIENCEDOMAIN international www.sciencedomain.org Nstemi But Stemi-De Winters Sign Prem Krishna
More informationComplications of Acute Myocardial Infarction
Acute Myocardial Infarction Complications of Acute Myocardial Infarction Diagnosis and Treatment JMAJ 45(4): 149 154, 2002 Hiroshi NONOGI Director, Division of Cardiology and Emergency Medicine, National
More informationIn the name of GOD. Animal models of cardiovascular diseases: myocardial infarction & hypertension
In the name of GOD Animal models of cardiovascular diseases: myocardial infarction & hypertension 44 Presentation outline: Cardiovascular diseases Acute myocardial infarction Animal models for myocardial
More informationResults of Ischemic Heart Disease
Ischemic Heart Disease: Angina and Myocardial Infarction Ischemic heart disease; syndromes causing an imbalance between myocardial oxygen demand and supply (inadequate myocardial blood flow) related to
More informationPrediction of Life-Threatening Arrhythmia in Patients after Myocardial Infarction by Late Potentials, Ejection Fraction and Holter Monitoring
Prediction of Life-Threatening Arrhythmia in Patients after Myocardial Infarction by Late Potentials, Ejection Fraction and Holter Monitoring Yu-Zhen ZHANG, M.D.,* Shi-Wen WANG, M.D.,* Da-Yi Hu, M.D.,**
More informationSubject Index. Bcl-2, apoptosis regulation Bone marrow, polymorphonuclear neutrophil release 24, 26
Subject Index A1, apoptosis regulation 217, 218 Adaptive immunity, polymorphonuclear neutrophil role 31 33 Angiogenesis cancer 178 endometrium remodeling 172 HIV Tat induction mechanism 176 inflammatory
More informationCurriculum Vitae. Saeed Alipour Parsa, M.D., Associate Professor of Cardiology
Curriculum Vitae Saeed Alipour Parsa, M.D., Associate Professor of Cardiology Department of Interventional Cardiology Shahid Modarres hospital Shahid Beheshti University of Medical Sciences PERSONAL DATA
More informationGene expression was analyzed by real time PCR (SYBR GREEN PCR Master. Mix, Roche Applied Science) using specific oligonucleotides.
1 SUPPLEMENTAL MATERIAL SUPPLEMENT METHODS Real Time PCR. Gene expression was analyzed by real time PCR (SYBR GREEN PCR Master Mix, Roche Applied Science) using specific oligonucleotides. Rat ST2L forward
More informationZachary I. Hodes, M.D., Ph.D., F.A.C.C.
Zachary I. Hodes, M.D., Ph.D., F.A.C.C. Disclamer: I personally have no financial relationship with any company mentioned today. The Care Group, LLC does have a contract with Cardium to participate in
More information